SRR934833
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 72.89750328515112
- age_years
- 53
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.625
- INTERFERON_GAMMA_RESPONSE+0.531
- ALLOGRAFT_REJECTION+0.438
- PROTEIN_SECRETION+0.438
- TGF_BETA_SIGNALING+0.422
- IL6_JAK_STAT3_SIGNALING+0.399
- IL2_STAT5_SIGNALING+0.369
- MITOTIC_SPINDLE+0.367
- INFLAMMATORY_RESPONSE+0.362
- ANDROGEN_RESPONSE+0.318
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.424
- KRAS_SIGNALING_DN-0.377
- SPERMATOGENESIS-0.279
- ESTROGEN_RESPONSE_LATE-0.148
- MYOGENESIS-0.144
- ANGIOGENESIS-0.117
- E2F_TARGETS-0.077
- ESTROGEN_RESPONSE_EARLY-0.050
- HYPOXIA-0.005
- G2M_CHECKPOINT+0.002
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.921 |
| 2 | 896B5096-D888-4DC3-9C70-152BDE083E26 | — | — | 0.918 |
| 3 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.909 |
| 4 | 9ECB653A-A04F-457C-92FC-D13424511A47 | — | — | 0.906 |
| 5 | C1CCE12B-8892-49AB-8DF2-E5E280DEAE32 | — | — | 0.903 |
| 6 | 1C62E679-3A4E-4D10-8BFB-5BFBF2A3B4B6 | — | — | 0.900 |
| 7 | SRR934807 | — | — | 0.898 |
| 8 | 385ECC71-2BF4-4E14-B2CC-8423E79BDEBE | — | — | 0.897 |
| 9 | SRR934830 | — | — | 0.893 |
| 10 | SRR934811 | — | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.625 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.531 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.438 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.438 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.422 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.399 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.369 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.367 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.362 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.318 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.317 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.308 | Inavolisib | — uncovered |
| COMPLEMENT | 0.308 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.242 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.239 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.215 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.214 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.194 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.186 | Inavolisib | — uncovered |